HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antonio J Grillo-López Selected Research

Non-Hodgkin Lymphoma (Lymphosarcoma)

2/200590Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
12/2004Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
12/2003Rituximab (Rituxan/MabThera): the first decade (1993-2003).
4/2003Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
10/2002Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma.
6/2002Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
5/2002Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
2/2002Rituximab: ongoing and future clinical development.
2/2002Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
2/2002Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Antonio J Grillo-López Research Topics

Disease

13Non-Hodgkin Lymphoma (Lymphosarcoma)
02/2005 - 02/2002
9Neoplasms (Cancer)
04/2013 - 02/2002
4Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
10/2002 - 02/2002
3Lymphoma (Lymphomas)
12/2003 - 06/2002
2B-Cell Lymphoma (Lymphoma, B Cell)
12/2004 - 12/2002
2Thrombocytopenia (Thrombopenia)
04/2003 - 06/2002
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
04/2013
1Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
10/2005
1Disease Progression
12/2004
1Hematologic Neoplasms (Hematological Malignancy)
12/2003

Drug/Important Bio-Agent (IBA)

13Rituximab (Mabthera)FDA Link
04/2013 - 02/2002
8ibritumomab tiuxetan (Zevalin)FDA Link
02/2005 - 02/2002
4AntibodiesIBA
04/2013 - 02/2002
4Monoclonal AntibodiesIBA
12/2002 - 02/2002
2Prednisone (Sone)FDA LinkGeneric
04/2013 - 12/2004
2Vincristine (Oncovin)FDA LinkGeneric
04/2013 - 12/2004
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
04/2013 - 12/2004
2YttriumIBA
02/2002 - 02/2002
2fludarabineIBA
02/2002 - 02/2002
1Doxorubicin (Adriamycin)FDA LinkGeneric
12/2004
1thiamine triphosphorate (TTP)IBA
12/2004

Therapy/Procedure

10Therapeutics
04/2013 - 02/2002
9Radioimmunotherapy
02/2005 - 02/2002
5Drug Therapy (Chemotherapy)
04/2013 - 02/2002
2Combination Drug Therapy (Combination Chemotherapy)
02/2002 - 02/2002
2Radiotherapy
02/2002 - 02/2002
1Immunotherapy
05/2002